{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:12:39Z","timestamp":1791807159742,"version":"4.3.4"},"reference-count":49,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2021,5,3]]},"DOI":"10.1080\/14656566.2021.1890026","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T22:25:19Z","timestamp":1613773519000},"page":"797-807","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date"],"prefix":"10.1080","volume":"22","author":[{"given":"Rhonda E","family":"Colombo","sequence":"first","affiliation":[{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, Medical College of Georgia\/Augusta University, Augusta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1315399"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306801"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.26"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0270-z"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy358"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa502"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix131"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.5.964"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9090539"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1701215"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9090558"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02068-16"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myz083"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-17"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa016"},{"key":"cit0017","unstructured":"Scynexis Press Release. Scynexis\u2019 oral SCY-078 receives FDA QIDP and Fast Track Designations for the treatment of VVC and prevention of recurrent VVC. 2018 May 1. Available at: https:\/\/www.scynexis.com\/news-media\/press-releases\/detail\/147\/scynexiss-oral-scy-078-receives-fda-qidp-and-fast-track"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01961-16"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00435-17"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02396-16"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1791820"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02145-13"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01588-12"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00234-15"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00244-18"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks466"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00161-17"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01102-17"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx010"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03255-14"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01692-19"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01510-19"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105922"},{"issue":"2","key":"cit0034","doi-asserted-by":"crossref","first-page":"e02119","DOI":"10.1128\/AAC.02119-18","volume":"63","author":"Wring S","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"cit0035","first-page":"e02269","volume":"64","author":"Lee A","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04445-14"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx422"},{"key":"cit0038","volume-title":"Abstract (no. F1-1975) presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Trucksis M","year":"2010"},{"key":"cit0039","volume-title":"Poster (no. F1-1390) presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Trucksis M","year":"2011"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1146"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.588"},{"key":"cit0042","volume-title":"Abstract (no. 172) presented American Society for Microbiology (ASM)","author":"Murphy G","year":"2017"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz277"},{"key":"cit0044","volume-title":"Presented at: 3rd International Society for Infectious Diseases in Obstetrics and Gynecology Congress","author":"Azie NA","year":"2019"},{"key":"cit0045","unstructured":"Scynexis Press Release. Scynexis announces SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection): SCYNEXIS, Inc. (SCYX). 2020 Apr 21. Available at: https:\/\/www.scynexis.com\/news-media\/press-releases\/detail\/207\/scynexis-announces-positive-top-line-results-from-its"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.2174\/1568026619666191025152412"},{"key":"cit0047","unstructured":"Juneja D, Singh O, Tarai B, et al. Successful treatment of two patients with Candida auris candidemia with the investigational agent, oral ibrexafungerp (formerly SCY-078) from the CARES Study; Poster (no. L0028) presented at: 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID): 2019 April 13\u201316. Amsterdam, Netherlands."},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1432"},{"key":"cit0049","unstructured":"Prattes J, Zurl C, Azie N, et al. Clinical Experience of Oral Ibrexafungerp for Treatment of Four Patients with Invasive Candidiasis from the FURI Study. In ECCMID 2020 Abstract Book. Abstract #988, page 524. Available at: https:\/\/www.escmid.org\/escmid_publications\/eccmid_abstract_book"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2021.1890026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T07:06:32Z","timestamp":1623740792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2021.1890026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,5,3]]}},"alternative-id":["10.1080\/14656566.2021.1890026"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2021.1890026","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}